Lusedra (Fospropofol) is a new sedative-hypnotic agent indicated for monitored anesthesia care during diagnostic or therapeutic procedures. It works by metabolizing into propofol. Standard dosing for induction is 6.5mg/kg by IV bolus, with supplemental doses of 1.6mg/kg as needed to maintain sedation. Common side effects include nausea, vomiting, headache, and hypotension. It provides moderate sedation and has more predictable pharmacokinetics than propofol.